09 November 2023 
EMA/CHMP/331542/2023 
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Veltassa 
patiromer 
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Veltassa. The marketing authorisation holder for this medicinal product is Vifor Fresenius Medical Care 
Renal Pharma France. 
The CHMP adopted a new pharmaceutical form and strength (1g powder for oral suspension) together 
with a new indication in paediatric patients. For information, the full indication for Veltassa will be as 
follows:2 
Veltassa is indicated for the treatment of hyperkalaemia in adults and adolescents aged 12 to 
17 years. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
